• In late March 2026, Agilent Technologies announced that Senior Vice President, Chief Legal Officer and Secretary Bret DiMarco will step down once a successor is in place or by September 30, 2026, and then remain as a Special Advisor through December 1, 2026, to support the transition.
• Separately, Agilent is showcasing new oncology-focused instruments and its collaboration with Oxford Nanopore Technologies at the American Association for Cancer Research Annual Meeting, underlining the company’s push to deepen its role in cancer research and diagnostics workflows.
• We’ll now examine how Agilent’s oncology technology showcase and Oxford Nanopore collaboration could influence the company’s longer-term investment narrative.

This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.

Agilent Technologies Investment Narrative Recap

To own Agilent, you need to believe in its role as a core supplier of instruments, consumables, and diagnostics across pharma, chemicals, and oncology workflows. The recent legal leadership transition and oncology-focused product showcase do not appear to materially change the near term focus on offsetting tariff pressures and managing funding softness in academic and government labs, which still looks like the key short term catalyst and the most immediate risk, respectively.

The most relevant update here is Agilent’s expanded oncology presence, including its collaboration with Oxford Nanopore at AACR, which reinforces efforts to grow higher margin recurring revenues tied to cancer research workflows. If successful, this could help deepen adoption of lab automation and digital tools highlighted at recent industry meetings, supporting the company’s push to balance capital equipment cycles with more resilient service and consumables income.

Yet even with these oncology opportunities, investors should be aware that rising tariff driven costs and supply chain complexity could still...

Agilent Technologies' narrative projects $8.6 billion revenue and $2.0 billion earnings by 2029. This requires 6.7% yearly revenue growth and about a $0.7 billion earnings increase from $1.3 billion today.

Uncover how Agilent Technologies' forecasts yield a $161.94 fair value, a 37% upside to its current price.

Exploring Other Perspectives

Five Simply Wall St Community fair value estimates for Agilent span roughly US$124.57 to US$161.94, showing how far apart individual views can be. When you weigh these against concerns about tariff driven margin pressure, it becomes even more important to compare several perspectives before forming an opinion on Agilent’s longer term performance potential.

Explore 5 other fair value estimates on Agilent Technologies - why the stock might be worth just $124.57!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Agilent Technologies research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free Agilent Technologies research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Agilent Technologies' overall financial health at a glance.

Ready For A Different Approach?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• We've uncovered the 11 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Uncover the next big thing with 29 elite penny stocks that balance risk and reward.
• Capitalize on the AI infrastructure supercycle with our selection of the 38 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.